According to the China Post Securities Research Report, Yao Ming Kangde's performance continued its strong trend, once again raised its full-year guidance, and the biology business began to meet AI4S/AIDD demand. The business remained strong, and capital expenditure guidelines were raised. Ongoing orders are growing at an accelerated pace, and the full-year performance guidelines have been raised again. Ongoing business orders amounted to 76.74 billion yuan, a net quarterly increase of about 10.3 billion yuan from 66.43 billion yuan at the end of Q2. In view of revenue and order trends in the first three quarters, the company raised the overall revenue guidance for the full year of 2026 from 585-60.5 billion yuan to 61-61.9 billion yuan, the revenue growth rate from continuing operations from 35-39% to 40-42%, and the adjusted free cash flow guideline from 135-14.5 billion yuan to 145-15.5 billion yuan. The company continues to promote AI and automation capacity building, empowering various business scenarios such as pharmacology and pathology, responding quickly to AIDD/AI4S customer needs, providing high-throughput, diversified, customized, comprehensive and integrated wet laboratory services, and building a new type of efficient and complementary cooperative relationship. The company is a leading pharmaceutical R&D service company. It has plenty of orders in hand, strong growth certainty, and maintains a “buy” rating.

According to the China Post Securities Research Report, Yao Ming Kangde's performance continued its strong trend, once again raised its full-year guidance, and the biology business began to meet AI4S/AIDD demand. The business remained strong, and capital expenditure guidelines were raised. Ongoing orders are growing at an accelerated pace, and the full-year performance guidelines have been raised again. Ongoing business orders amounted to 76.74 billion yuan, a net quarterly increase of about 10.3 billion yuan from 66.43 billion yuan at the end of Q2. In view of revenue and order trends in the first three quarters, the company raised the overall revenue guidance for the full year of 2026 from 585-60.5 billion yuan to 61-61.9 billion yuan, the revenue growth rate from continuing operations from 35-39% to 40-42%, and the adjusted free cash flow guideline from 135-14.5 billion yuan to 145-15.5 billion yuan. The company continues to promote AI and automation capacity building, empowering various business scenarios such as pharmacology and pathology, responding quickly to AIDD/AI4S customer needs, providing high-throughput, diversified, customized, comprehensive and integrated wet laboratory services, and building a new type of efficient and complementary cooperative relationship. The company is a leading pharmaceutical R&D service company. It has plenty of orders in hand, strong growth certainty, and maintains a “buy” rating.